Focused on Cures

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients

INNOVATIVE

Technology

Excision's cutting edge CRISPR gene therapy platform is built on technology licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.

We are the first company to remove HIV genomes from animals and generate functional cures for HIV.

NOVEL

Approach

SAFE

Targets non-human viral genomes minimizing chance of off-target cuts

CURATIVE

Removes non-human DNA to return the genome to normal or near-normal

EFFICIENT

Excision products require one-time gene edit to remove the viral genome permanently

“I am optimistic that Excision’s technology and approach using CRISPR could potentially cure infectious diseases and bring much needed therapies to those in need around the world.”

Jennifer Doudna, Ph.D., CRISPR Co-inventor

UC Berkeley, 2020

Publications

LATEST

GLOBE NEWSWIRE

August 2021

Excision BioTherapeutics Expands Management Team with Three Key Appointments

GLOBE NEWSWIRE

October 2021

Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV

GLOBE NEWSWIRE

September 2021

Temple Researchers Awarded Prestigious Grant from the NIH’s Martin Delaney Collaboratories for HIV Cure Research Program

Temple University

August 2021

OUR

Partners

info@excisionbio.com

499 Jackson Street
San Francisco, CA 94111
USA

© 2021 Excision BioTherapeutics. All Rights Reserved.